© 2026 Sinochem Nanjing Corporation,
All Right Reserved
The story of Ioversol Hydrolysate starts in the growing field of medical imaging, a journey that reflects decades of tight collaboration between chemists, doctors, and engineers. Radiology departments once relied on contrast agents with less-than-ideal safety profiles. Ioversol Hydrolysate entered the scene when manufacturers sought non-ionic, low-osmolarity solutions to minimize risk and discomfort for patients. Product patents and clinical trials from the late 1970s and early 1980s brought safer options, and this compound steadily gained ground thanks to its balance between clarity in imaging and a lower rate of side effects. Those who practiced medicine in the eighties remember the shift from ionic contrast agents, notorious for allergic reactions and toxicity, toward new molecules that promised better patient outcomes.
Ioversol Hydrolysate steps up in the world of contrast agents as a non-ionic, water-soluble derivative. Its use in CT and angiography marks a milestone in diagnostic medicine. Equipment and procedure protocols adapt to its chemical stability, consistency in dose response, and ability to clear quickly from the body. Manufacturers package it in sterile, single-use vials, keenly aware of contamination risks in hospital environments. This agent, known for its superior imaging capability, helps clinicians identify life-threatening conditions with sharper accuracy and less risk to fragile or allergic patients. Administration methods—intravenous or intra-arterial—reflect the versatility expected in busy radiology suites, where time and safety stand as top priorities.
Density, viscosity, and osmolality define Ioversol Hydrolysate’s physical profile. Its clear, colorless appearance signals both purity and ease of monitoring prior to administration. Solubility in water runs high, thanks to its configuration, and the molecule remains non-ionic under physiological conditions. With a molecular weight typically around 807 Da, it draws water without causing excessive fluid shifts in vascular compartments—a problem that plagued earlier agents. Temperature stability under typical storage conditions extends shelf-life and eases logistics for busy pharmacies. I’ve seen radiologists rely on its low viscosity for smooth injection through catheters, especially important when time is of the essence in the angiography lab.
Labeling guidelines emphasize concentration, batch number, expiry date, and usage instructions in plain language. Regulatory agencies now push for detailed traceability; every vial provides a full breakdown of iodine content per milliliter, osmolality, pH, and recommended storage conditions. Training in reading this data becomes critical—errors in dose calculation can harm patients, especially those with compromised kidney function. Technology supports safety, with machine-readable barcodes to match doses with patient records. Professionals receive ongoing instruction to understand not only how much to administer but also how to handle recall or disposal when products fall out of specification.
Production begins with complex organic synthesis routes, using iodinated aromatic compounds as starting materials. Stringent purification steps—typically high-performance liquid chromatography—ensure a product free from impurities that might complicate image interpretation or trigger patient reactions. Strict aseptic conditions during bottling matter more with sensitive diagnostic agents than with many other hospital supplies. Automation in production lines protects both users and end-users from cross-contamination. I’ve witnessed the raw strictness applied to cleaning and sterilizing lines between batches, as even trace cross-contact can halt a production run and waste significant resources.
Development teams engineer Ioversol Hydrolysate through targeted reactions introducing specific side chains and iodination patterns. Core aromatic rings, typically benzene derivatives, receive iodine atoms at carefully chosen positions, maximizing radiodensity while minimizing osmotic pressure in the blood. Segmentation of synthesis steps—base reactions, hydrolysis, and further modification—mirror the industry’s focus on reproducibility and scale. Research teams tweak functional groups to improve water solubility or reduce rates of protein binding, always aware that structural changes mean new rounds of stability and efficacy testing.
Across different regions, Ioversol Hydrolysate carries various trade names and catalog numbers, each locked to specific specifications. The name Ioversol sticks in Asia, Europe, and the Americas, yet product leaflet details differ slightly between markets—each influenced by local regulatory standards. Those who’ve ordered supplies internationally know about the confusion over synonyms and international nonproprietary names, a recurring headache for procurement officers and clinicians trying to match hospital formularies with vendor inventories. Consistency in naming shaves off precious minutes during emergencies, as clinicians can spot and verify the agent needed for a procedure.
Manufacturers and health care systems treat safety standards with urgency; the rise of strict pharmacovigilance follows mishaps with older agents. Pre-screening patients for allergies and renal function matter more than ever, especially as new data emerge about patients at higher risk for contrast-induced nephropathy. Operational standards extend to technician training, emergency protocols in case of reactions, and waste handling policies to prevent environmental contamination. In our own training sessions, mock drills involving simulated allergic reactions kept staff sharp and ready. Regulatory bodies conduct surprise inspections to check not only product quality but also staff preparedness.
Hospitals and diagnostic centers use Ioversol Hydrolysate in everything from CT scans of the abdomen to angiograms that map out the arteries of the heart and brain. This agent finds its place in both emergent trauma care and routine cancer screenings. My own experience in working with interventional radiologists highlights how rapid, reliable imaging depends on agents that perform predictably—no sudden viscosity changes, no clotting, no reactivity in unpredictable clinical scenarios. Specific patient groups—children, the elderly, those with pre-existing health conditions—reap tangible benefits from an agent that offers high detail and a lower threshold of risk.
The push for better contrast agents presses on. Research teams investigate how tweaks in the molecular backbone or peripheral side chains influence not just image quality but also how the human body processes and eliminates the compound. I’ve read about animal studies targeting longer retention times for improved oncology imaging, and human trials looking at ways to predict and prevent kidney damage. Digital advances feed back into chemistry—machine learning helps model which modifications might increase solubility or decrease allergenicity, creating a virtuous cycle of experimentation and improvement.
Clinical safety data build up year by year, with long-term surveillance efforts tracking rates of mild and severe reactions. Researchers now look beyond standard acute toxicity, focusing on subtle impacts of repeated exposures. Academic studies explore links between repeated contrast use and changes in renal function, even among those not previously thought at risk. Animal models and human cohort studies contribute to updated pre-screening recommendations. My own colleagues in nephrology emphasize close collaboration with radiology to manage doses and time intervals between scans, tailoring imaging choices to the patient's entire clinical picture.
The next decade promises even more customizable contrast agents. Advances in synthetic chemistry, coupled with big data in genomics, suggest the era of ‘one-size-fits-all’ will fade. Health care providers could receive guidance based on individual patient genotypes or biomarkers, reducing risk and boosting diagnostic yield. Sustainability also pushes upward; manufacturers look to minimize environmental residues of iodinated agents in water supply. Regulatory agencies may soon require new transparency in both clinical and environmental safety profiles as part of product approval. Continuous dialogue among chemists, clinicians, and patient advocacy groups stands out as the path forward as medicine seeks both sharper images and safer lives.
Most people aren’t familiar with the name Ioversol Hydrolysate. When I first heard about it in a hospital radiology discussion, I had to stop and ask a radiologist about it. His answer was simple: Ioversol Hydrolysate matters for people who need certain types of medical imaging. The backbone of many CT scans today relies on substances like this. As a contrast agent, it helps doctors spot details inside the body they wouldn’t see on a regular scan.
Getting a clear picture of organs, blood vessels, or tumors often means injecting something that stands out on the screen. Ioversol Hydrolysate shows up strongly on X-ray and CT images. It’s not just another dye. Doctors use it because it’s water-soluble, slides through the body and flushes out through the kidneys, reducing the risk of long-term buildup. This matters a lot for patients who come in with kidney concerns or allergies.
My own family experience made this personal. A close relative faced a cancer scare a few years back. The imaging team used Ioversol Hydrolysate for her CT scans. We worried about allergic reactions—especially after hearing stories about older contrast dyes causing problems. Thankfully, the radiology nurse reassured us, explaining that modern agents like Ioversol Hydrolysate are less likely to trigger such issues. She also pointed out how radiologists always monitor patients during scans. That care, rooted in research and experience, is backed by data: a review in the journal “Radiology” reported that severe allergic responses happen far less often now, resting below one in several thousand cases.
Hospitals face regular shortages and price hikes with specialized agents like Ioversol Hydrolysate. These supply chain hiccups trickle down to patient care, leading to scan delays or substitutions with older, less reliable agents. Many doctors and pharmacists advocate for building better reserves and closer supply partnerships. Tracking usage and making sure no dose goes to waste is already routine in busy imaging centers, but pressure keeps growing as demand climbs.
Some patients worry about long-term side effects. Research so far suggests that Ioversol Hydrolysate leaves the body quickly. For most people, it’s out within a day or so. In clinics, extra attention goes to those with a history of kidney problems or reactions to previous contrast media. Doctors double-check kidney function and offer hydration, reducing the risk even more. These practices reflect lessons learned from years of feedback and clinical trial data, including findings from the FDA and leading hospitals.
Healthcare faces a challenge: balancing innovation, safety, and cost. Newer contrasts like Ioversol Hydrolysate prove that progress in imaging doesn’t stand still. Hospitals work around shortages by coordinating across networks and training staff to spot early signs of trouble. Telemedicine check-ins grow popular, so patients with questions about scans or risks can talk with a clinician before and after the procedure. Patients who understand what’s being injected into their bodies show lower anxiety and report better experiences overall, a fact supported by several patient advocacy surveys.
The takeaway? Staying informed about substances like Ioversol Hydrolysate builds trust between patients and clinicians. With thoughtful use, ongoing research and open communication, imaging centers help people get answers when they need them most.
Medical imaging pulls back the curtain on what’s going on inside a patient’s body. Without contrast agents, doctors miss key details. Ioversol hydrolysate helps clear up the picture in CT scans and other radiology tests. It’s been used for years, and plenty of research tracks both the positives and the concerns.
There’s always a bit of nervousness about what goes into your body before a scan. In hospitals, patients sometimes ask if these contrast agents are “dangerous.” That’s understandable. Not everyone reads medical journals or talks to radiologists daily.
Doctors pay close attention to safety. Their first line of defense is a patient’s medical history. Ioversol hydrolysate gets flagged for those with allergies to iodine or kidney issues. Past studies, including a review in the journal Radiology, looked at thousands of patient cases. Most got through imaging with no more than a short-lived warm sensation or a metallic taste.
Serious reactions do crop up from time to time. That means trouble breathing, rash, or in rare cases, anaphylaxis. A review from the American College of Radiology notes severe allergic response rates land around 0.01% for non-ionic contrast agents like ioversol—less than one in ten thousand. Compared with older contrast agents, modern versions such as ioversol hydrolysate cause fewer problems.
Concerns flare up about contrast-induced nephropathy, especially for people with existing kidney trouble or diabetes. Doctors still debate whether non-ionic agents like ioversol hydrolysate increase the risk. Guidelines now recommend proper hydration before and after the scan. For patients on certain medications like metformin, some clinics pause the drug until bloodwork confirms the kidneys still work well. Having watched radiology teams over the years, I’ve seen them monitor lab numbers like creatinine before approving a contrast scan.
The U.S. Food and Drug Administration approves ioversol hydrolysate, and the European Medicines Agency gives it the green light after routine checks. Both agencies watch for side effects as cases get reported. Their data shows no hidden pattern of new risks. The American College of Radiology and the Radiological Society of North America both say use is justified for most people, given current evidence.
Trust starts with communication. Radiology staff answer questions about what patients can expect when injected with ioversol hydrolysate. Honest answers help ease worries. Every hospital I’ve worked in keeps emergency meds close, ready for any odd reaction—even if it’s unlikely. After a scan, staff ask if patients feel different or notice swelling, rash, or trouble breathing.
For patients worried about rare side effects or kidney risk, it helps to know hospitals check on allergies and lab results long before the scan. Keeping everyone informed reduces anxiety and smooths the process. It’s not just about safer tests—it’s about treating people right.
Ioversol hydrolysate stands out as a contrast agent. Doctors rely on it during imaging procedures to help visualize organs and blood vessels more clearly. It slides into the bloodstream through a vein, helping radiologists grab sharper images. Like a lot of drugs injected for imaging, ioversol hydrolysate brings up a main question: what side effects do people actually face?
Feeling an unusual warmth comes up often. That rush, spread around the chest, neck, or groin, doesn’t last long—maybe a minute or two. Nausea, a metallic taste in the mouth, and mild headaches can show up. In my experience talking with healthcare professionals, most people shrug these off once the test finishes. These side effects rarely disrupt the imaging, and patients often forget about them soon after walking out of the hospital.
Some people report itching, hives, or a rash—classic signs of an allergic response. Itching by itself often settles with basic observation, but hives or swelling might prompt the care team to act faster. It’s not just about a rash; swelling in the throat or face, a drop in blood pressure, or trouble breathing means real trouble. Aspiring to provide safe care, clinics watch patients closely during and right after the injection for these reasons.
The kidneys filter substances out of our blood. Injecting any contrast dye, including ioversol hydrolysate, makes the kidneys work harder. Studies and clinical experience show most healthy folks don’t suffer kidney trouble from a single low dose. For people with chronic kidney disease or older adults with hidden risk factors, the chance of kidney injury bumps up. On rare occasions, doctors have seen “contrast-induced nephropathy,” which means a detectable drop in kidney function after the procedure. Reviewing pre-existing kidney labs and considering hydration has helped lower this risk in busy hospitals.
Itching or rashes sometimes develop several hours after leaving the hospital. This isn’t common and tends to resolve with over-the-counter remedies. While not often dangerous, no one likes surprise reactions after what should be a routine day. Education and outreach make a difference: if people know what to watch for, they feel more confident handling mild problems.
Doctors and nurses weigh risks versus benefits before using any contrast dye. Electronic records flag allergies, and history-taking brings up previous bad experiences. On the day of the scan, clear communication keeps everyone on the same page. If a reaction ever kicks off, having emergency drugs and trained staff around can save lives. For folks at greater risk, using less dye or an alternative approach comes up for discussion.
Knowing about these reactions isn’t just a footnote—it gives patients and families power. Too many people step into imaging appointments anxious or unaware. Understanding what might happen, what’s unusual, or when to call for help, changes the whole experience. That’s good medicine. People deserve plain answers and a team prepared for anything.
Hospitals keep tools in their kit for a reason. Ioversol hydrolysate shows up during imaging studies, such as CT scans, to help doctors see what they might miss on a regular X-ray. Once injected, it circles through the bloodstream, highlighting vessels and organs. After working in hospital radiology, I’ve seen these injections clear up confusion about symptoms or unknown pain.
Most folks experience this stuff through intravenous (IV) injection. Nurses start by locating a good vein in the arm. Sometimes, problems like dehydration or tricky veins slow things down. Not every patient knows that anxiety can cause veins to shrink, so a little breathing space helps. The nurse cleans the area, puts in a needle, and hooks up a syringe or an automated power injector, depending on the scan type and protocol.
Technicians check and double-check the medical history for allergies or thyroid conditions before moving forward. People with shellfish allergies sometimes worry. Current guidelines state iodine allergies—one of the main concerns—don’t always line up with reactions to modern agents like Ioversol hydrolysate. Still, staff stand ready with emergency supplies in case anyone reacts.
Patients often describe a warm flush or odd taste in the back of the mouth shortly after administration. These side effects fade quickly. Others report nausea or mild headaches. Rarely, more serious reactions crop up. My time in the imaging suite taught me the importance of staying with the patient for several minutes after the dye has run its course.
Education helps. Those who know what’s coming tend to handle the process better. Involving patients every step of the way cuts confusion and fear. Less anxiety leads to smoother procedures and better images.
Every patient brings a different story. Dosage depends on body weight, age, and kidney status. Doctors adjust volumes or sometimes opt out for folks with kidney disease. Proper hydration before and after injection works wonders in flushing out contrast from the system. Kidney functions play a pivotal role. For older adults or those with diabetes, the care team pays extra attention to minimize risk and keeps fluids moving through IV drips post-procedure.
Kids present a different challenge. The smaller veins and lower body mass mean experienced hands must step in. Pediatric nurses and techs usually work together, drawing from plenty of practice and continued training. Both teamwork and child-friendly explanations make these scans much less scary for children and guardians alike.
Despite advances, hurdles still come up. Some rural clinics struggle with access to safer, low-reactivity contrast agents like Ioversol hydrolysate. Younger staff benefit from shadowing more experienced coworkers to build confidence in tough situations. Ongoing education remains critical, not just for staff but for patients, who get better results when they arrive calmer and informed. Hospitals must keep up with the latest guidelines, keeping emergency meds in every suite and learning from every close call.
Quality care means more than just getting the scan done. It shows up in the comfort provided, the clear explanations given, and the quick action if something unexpected happens. All these small steps add up to better—safer—image-guided care.
Stepping into any imaging room, parents, patients, or staff always feel a little tension brewing over contrast agents. Ioversol hydrolysate acts as a water-soluble contrast medium; it lets doctors spot issues on X-rays or CT scans they would otherwise miss. But a clear scan is only half the story. What really matters is how the human body reacts to this type of product—in real time and in recovery. In medical work, cutting corners or gliding past contraindications causes harm. Patients bring up allergies or kidney issues. Doctors can't wave those aside and hope for the best.
Allergic reactions sit at the front of the list. A good number of people deal with allergies to iodine-containing substances. I’ve had patients who don't mention their shellfish allergies—until the hives break out and their breathing turns shallow after injection. Whether a person’s reaction comes from iodine itself or a broader pool of sensitivities, it can get serious fast. We see anything from mild rashes to anaphylaxis, and every year, some folks wind up in the ER.
Kidney function plays a huge role, too. People with long-term diabetes or heart failure tend to walk into hospitals with kidneys already under pressure. Tossing ioversol hydrolysate into the mix adds another hurdle. There's a term for this: contrast-induced nephropathy. It isn't rare; studies show up to 10% of at-risk hospital patients face worsening kidney function after receiving certain contrast agents. Even a healthy adult should drink extra fluids for a day after imaging, but those with chronic kidney disease risk complications that don’t fade.
Taking metformin comes up in clinics again and again. The problem lies in how metformin and ioversol interact inside the body. If kidney function dips after injection, lactic acid can build up. Lactic acidosis sounds rare, but it’s not just a scary textbook term; it lands real patients in intensive care units. Pharmacists and nurses keep metformin on hold before and after, just to give the body space to clear everything out.
Talking through current drugs, allergies, and chronic illnesses proves essential. Hospital staff always ask the same questions for a reason. People with thyroid problems—especially those with a hot nodule or untreated Graves’ disease—may face new or worsened symptoms after an iodine-based contrast. Those who’ve suffered major dehydration, myeloma, or have undergone organ transplants tread deeper waters because of the extra strain on their system.
Pregnant or breastfeeding moms deserve an extra seat at the table. Limited research means the risks aren’t fully mapped out, so decisions here get made conservatively and with the whole healthcare team pulling together.
Before shooting up any contrast dye, hospitals can run kidney checks, hydrate patients ahead of time, and flag high-risk teams as backup. Smart prep doesn’t take hours—sometimes it’s just a couple of extra blood tests and a strong conversation built on trust. I’ve seen clinics set out hydration stations, and it’s made a difference. Informed choices and hard questions keep people safer, so a scan reveals truth, not trouble.
Health care runs on teamwork and straight talk. Rushing through safety checks isn’t an option; every step makes a difference in the picture that gets painted—on film and in real life.
| Names | |
| Preferred IUPAC name | 2,4,6-Triiodo-5-(N-methylacetamido)-N, N'-bis(2,3-dihydroxypropyl)isophthalamide |
| Other names |
Ioversol Hydrolysate Ioversol impurity Ioversol related compound Ioversol degradation product |
| Pronunciation | /ˌaɪ.oʊˈvɜːr.səl haɪˈdrɒl.ɪ.seɪt/ |
| Identifiers | |
| CAS Number | 114088-38-5 |
| 3D model (JSmol) | `3D Model (JSmol) String for Ioversol Hydrolysate: C1=CN(C(=O)N(C1=O)COC(C(C2=CC=CC=C2)NC(=O)CO)O)C` |
| Beilstein Reference | 68268-22-2 |
| ChEBI | CHEBI:136782 |
| ChEMBL | CHEMBL2106434 |
| ChemSpider | 13318020 |
| DrugBank | DB09141 |
| ECHA InfoCard | The ECHA InfoCard of product "Ioversol Hydrolysate" is: "03bc6e18-cbaf-4409-b301-2e674a8a1953 |
| EC Number | 234-384-2 |
| Gmelin Reference | 841564 |
| KEGG | C14239 |
| MeSH | D02.886.369.075.500, D02.886.670.267.500 |
| PubChem CID | 147311896 |
| RTECS number | V45284 |
| UNII | L1Q0WXP6UW |
| UN number | UN3332 |
| CompTox Dashboard (EPA) | DTXSID7046796 |
| Properties | |
| Chemical formula | C18H24I3N3O9 |
| Molar mass | 1200.09 g/mol |
| Appearance | Colorless or pale yellow liquid |
| Odor | Odorless |
| Density | 1.52 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -2.47 |
| Acidity (pKa) | 7.6 |
| Basicity (pKb) | pKb: 7.24 |
| Magnetic susceptibility (χ) | Negligible |
| Refractive index (nD) | 1.428 |
| Viscosity | 11.0 cP |
| Dipole moment | 2.41 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 322.6 J·mol⁻¹·K⁻¹ |
| Pharmacology | |
| ATC code | V08AB10 |
| Hazards | |
| Main hazards | May cause allergic skin reaction. Causes serious eye irritation. |
| GHS labelling | GHS07, GHS08 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | No hazardous statements. |
| Precautionary statements | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice/attention. |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | > 93°C |
| Lethal dose or concentration | LD₅₀ (rat, intravenous): > 10,000 mg/kg |
| LD50 (median dose) | LD50 (median dose): 7925 mg/kg (Rat, oral) |
| NIOSH | Not Listed |
| PEL (Permissible) | PEL not established |
| REL (Recommended) | 550 mgI/ml |
| Related compounds | |
| Related compounds |
Iodixanol Iohexol Iopamidol Ioversol Iopromide |
